Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables

International Journal of Mycobacteriology

Volumn 5, Issue 1, 2016, Pages 1-6

  Kambli, Priti ^a   Ajbani, Kanchan ^a   Nikam, Chaitali ^a   Sadani, Meeta ^a   Shetty, Anjali ^a   Udwadia, Zarir ^a   Georghiou, Sophia B ^b   Rodwell, Timothy C ^b   Catanzaro, Antonino ^b   Rodrigues, Camilla ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Drug susceptibility testing; Extremely drug resistant tuberculosis; Level of resistance; Mutations

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; TUBERCULOSTATIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; EIS PROTEIN, MYCOBACTERIUM TUBERCULOSIS; RNA 16S;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATION ANALYSIS; EIS GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RRS GENE; WILD TYPE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPE; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; RNA GENE;

AMIKACIN; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CAPREOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, RRNA; GENOTYPE; HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PROMOTER REGIONS, GENETIC; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84959102843     PISSN: 22125531     EISSN: 2212554X     Source Type: Journal    
DOI: 10.1016/j.ijmyco.2015.09.001     Document Type: Article

References (19)

1. Calver A.D., Falmer A.A., Murray M., et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg. Infect. Dis. 2010, 16:264-271.
2. Parsons L.M., Somoskovi A., Gutierrez C., et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin. Microbiol. Rev. 2011, 24:314-350.
3. Pfyffer G.E., Bonato D.A., Ebrahimzadeh A., et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J. Clin. Microbiol. 1999, 37:3179-3186.
4. Sirgel F.A., Tait M., Warren R.M., et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb. Drug Resist. 2012, 18:193-197.
5. Maus C.E., Plikaytis B.B., Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2005, 49:3192-3197.
6. Capreomycin. Tuberculosis (Edinb) 2008, 88:89-91.
7. Migliori G.B., Lange C., Centis R., et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 2008, 31:1155-1159.
8. Jugheli L., Bzekalava N., de Rijk P., et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother. 2009, 53:5064-5068.
9. Via L.E., Cho S.-N., Hwang S., et al. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis. J. Clin. Microbiol. 2010, 48:402-411.
10. Sowajassatakul A., Prammananan T., Chaiprasert A., et al. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiol. 2014, 14:165.
11. Rodrigues C., Jani J., Shenai S., et al. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int. J. Tuberc. Lung Dis. 2008, 12:1449-1455.
12. Ajbani K., Nikam C., Kazi M., et al. Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments. PLoS ONE 2012, 7:e49433.
13. Lin S.Y., Rodwell T.C., Rider T.C., et al. Pyrosequencing for rapid detection of extensively resistant Mycobacterium tuberculosis in clinical isolates. J. Clin. Microbiol. 2014, 52:475-482.
14. Bottger E.C. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 2011, 17:1128-1134.
15. Coyne K.M., Pozniak A.L., Lamorde M., et al. Pharmacology of second line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009, 23:437-446.
16. Gikalo M.B., Nosova E.Y., Lumila Y., et al. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J. Antimicrob. Chemother. 2012, 67:2107-2109.
17. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard 2011, Clinical and Laboratory Standards Institute, Wayne, PA. second ed.
18. Zaunbrecher M.A., Sikes R.D., Metchock B., et al. Overexpression of the chromosomally encoded aminoglycoside acetyl transferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2009, 47:20004-20009.
19. Magnet S., Blanchard J.S. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 2005, 105:477-498.